The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell, MD, James Cook University Hospital in Middlesbrough, UK, provides insight into the Phase III STABLE-MATES study (NCT02468024) comparing sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) in high-risk patients with stage I non-small cell lung cancer (NSCLC). Dr Peedell emphasizes the importance of recruiting more UK centers to ensure full recruitment, noting the potential transformative impact on understanding the role of surgery and radiation therapy in stage one disease. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
